Lupin Partners With Biomm To Launch Pegfilgrastim Biosimilar In Brazil
Filing For The Neulasta Biosimilar Was Accepted By The US FDA In June
Indian pharma firm Lupin has partnered with Biomm to market its proposed Neulasta biosimilar in Brazil, as it comes to the end of a tumultuous 2021.
You may also be interested in...
Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.
Lupin’s Q2 was a tale of three generics settlements – on Glumetza, which is still a commercial win despite the quarter-billion dollar outgo so far, on Spiriva, which will likely lead to happy tidings next fiscal year, and on Revlimid, on which the company has yet to make up its mind.
Lupin insists it has a “comprehensive remediation plan” to address deficiencies identified at its Novel Laboratories facility in New Jersey by an FDA warning letter. The Indian company says it does not anticipate any near-term commercial impact or supply disruptions linked to the letter.